We collected information about Akashi Therapeutics Inc Hours for you. Follow the liks to find out everything about Akashi Therapeutics Inc Hours.
https://www.akashirx.com/
Akashi Therapeutics is a clinical stage biopharmaceutical company. Our mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. Akashi is developing a ...
https://www.linkedin.com/company/akashi-therapeutics-inc-
Akashi Therapeutics, Inc. | 494 followers on LinkedIn. Akashi Therapeutics is a clinical stage biotechnology company developing a portfolio of products for …
https://www.crunchbase.com/organization/dart-therapeutics
Phone Number 617-431-7250. Akashi Therapeutics formerly known as Dart Therapeutics Inc. Akashi Therapeutics is a clinical stage biopharmaceutical company. Our mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi was founded by leading patient organizations and biotechnology industry veterans and is managed …
https://www.bizapedia.com/ma/akashi-therapeutics-inc.html
Akashi Therapeutics, Inc. is a Massachusetts Foreign Corporation filed On April 10, 2013. The company's File Number is listed as 001104595. The Registered Agent on file for this company is Marc Blaustein and is located at 245 First Street, 18th Floor, Cambridge, MA 02142.
https://digitgaps.com/report-store/akashi-therapeutics-inc-company-profile-financial-and-strategic-swot-analysis-mergers-and-acquisitions-partnerships-and-investments-news-key-profiles-and-competitors-report/
Akashi Therapeutics, Inc., a clinical stage biopharmaceutical company, develops treatments for Duchenne muscular dystrophy (DMD) and other rare pediatric diseases. It offers HT-100, an orally available small molecule drug candidate to reduce fibrosis and inflammation and to promote healthy muscle fiber regeneration in DMD patients; and DT-200, an oral selective androgen …
https://www.akashirx.com/pipeline/
AT-300 is a modified form of a peptide discovered in the venom of the Chilean Rose Tarantula that addresses calcium level imbalance in muscle, an early trigger of critical pathologies in DMD muscle that lead to loss of function. It is the only known specific inhibitor of the stretch-activated class of calcium ion channels. Originally discovered ...
https://www.grunenthal.com/en/press-room/press-releases/2016/pr-gruenenthal-and-akashi-therapeutics-inc-announce-joint-drug-development-program-for-ht-100-dmd
Grünenthal joins forces with Akashi Therapeutics Inc., a company founded by leading patient organizations, to combine skills and capabilities in a unique way for the benefit of patients with DMD. The alliance could in the future be expanded in the effort to the search for improvements for the treatment of boys and young men affected by DMD.
https://www.marketwatch.com/press-release/global-duchenne-muscular-dystrophy-drugs-market-business-trade-revenue-profit-and-loss-market-players-akashi-therapeutics-inc-antisense-therapeutics-ltd-beech-tree-labs-inc2022-2027-2021-09-09
Global Duchenne Muscular Dystrophy Drugs Market Business, Trade, Revenue, Profit and Loss Market Players (Akashi Therapeutics Inc, Antisense Therapeutics Ltd, Beech Tree Labs Inc)2022-2027 ...
http://www.sciguru.org/newsitem/17671/tarantula-venom-shows-promise-treating-fatal-form-childhood-muscular-dystrophy
Akashi Therapeutics Inc., a clinical-stage biopharmaceutical company, has acquired the rights to a drug that University at Buffalo scientists have begun developing for Duchenne muscular dystrophy, a common, fatal genetic disease affecting young boys. The potential therapy is called AT-300. It is a modified form of a small protein UB researchers first discovered in the venom of …
Searching for Akashi Therapeutics Inc Hours?
You can just click the links above. The info is collected for you.
